AlphAIAlphAI — Financial news for AI agents
tradingview.com$CBKM

Consumers Bancorp 3Q 2026: Revenue $12.37M, EPS $0.96 — 10-Q Summary

Consumers Bancorp reported 3Q 2026 revenue of $12.37M, up 12.3% YoY, with net income rising 15.3% to $3.04M. EPS increased to $0.96. Growth was driven by higher interest-earning assets, debit-card usage, and loan expansion, partially offset by higher salaries. Net interest margin improved to 3.52%.

Original reporting
tradingview.com
Published Nov 10, 2026, 7:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 7:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Consumers Bancorp 3Q 2026: Revenue $12.37M, EPS $0.96 — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$CBKMBullishMed
01

Why it matters

Positive earnings could attract short‑term buying interest, but modest scale limits broader market impact.

02

Market read

Earnings beat may provide a short‑term catalyst for the stock, with limited spillover to the broader banking sector.

03

What to watch

Higher employee costs could pressure margins if rates fall.

Relevance 6/10Novelty 8/10Timing: post‑market filing

Background

Consumers Bancorp filed its 10‑Q for Q1 2026, highlighting improved net interest income and loan growth.

Company-level read

Ticker impact

$CBKMBullishHigh confidence
Context

Consumers Bancorp reported Q1 2026 results with revenue $12.37M and EPS $0.96, both up YoY.

Expected impact

modest upside as market prices in the earnings beat

Evidence & confidence

Revenue rose 12.3% and EPS rose 14.3% YoY, indicating improved profitability and could lift the stock.

Market effects

Sector

Shows strength in regional community banking sector.

Regional

May boost sentiment for small‑cap banks in the U.S. Midwest.

Global

Limited to U.S. regional banking niche.

Counterpoint

What could challenge this read

Small‑cap banks remain vulnerable to rate volatility despite earnings beat.

Key entities

  • company
    Consumers Bancorp

    U.S. regional bank reporting Q1 2026 results.

Read at source← All news

Related articles

$CBKMMed

CONSUMERS BANCORP INC /OH/ (CBKM): Results of Operations and Financial Condition

CONSUMERS BANCORP INC /OH/ (CBKM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Consumers Bancorp, Inc. Reports: ● Net income increased by $404 thousand, or 15.3%, to $3.0 million for the three-month period ended September 30, 2026 compared with the same period last year. ● Net interest income increased by $1.2 million, or 12.9%, for the three-m

SEC EDGAR 8-K
$CBKMMed

CONSUMERS BANCORP INC /OH/ (CBKM): Results of Operations and Financial Condition

CONSUMERS BANCORP INC /OH/ (CBKM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Consumers Bancorp, Inc. Reports: ● Net income increased by $665 thousand, or 29.0%, for the three-month period and by $2.5 million, or 28.8%, for twelve-month period ended June 30, 2026, compared with the same periods last year. ● Net interest income increased by $1.

SEC EDGAR 8-K
$AXONMed

Axon Sinks 27% in a Week to a New 52-Week Low. Is the Selling Overdone?

Axon shares dropped 27% in a week to a 52-week low after missing Q3 revenue estimates and lowering its 2026 outlook due to delayed federal Dedrone deployments. The company now expects $350M-$400M in free cash flow by 2026, down from $450M, and needs $450M in Q4 to meet targets. Competitors Motorola Solutions and Tyler Technologies reported strong demand. Analysts reduced 2027 EPS estimates to $9.55 from $10.51.

finance.yahoo.com
$INOHighAI 8/10

Inovio Q3 2026 slides: VOCERYQ approval amid wider loss

Inovio Pharmaceuticals reported a Q3 2026 net loss of $49.2M, wider than expected, despite FDA approval of VOCERYQ. Shares fell 3.97% to $1.45, then another 10.34% after hours. Operating expenses declined 7% YoY, but non-cash losses increased. Cash reserves total $48.4M, with a runway into late 2027. VOCERYQ targets recurrent respiratory papillomatosis, showing 50-100% surgery reduction in trials. The company plans a Q1 2027 launch and European filings by year-end.

investing.com